$EVMN
Evommune, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Palo Alto, CA
EVMN chart
What traders are saying about $EVMN
Latest postsEvommune, Inc. news
- Evommune (EVMN) Short Interest & Short Float | Updated Oct 2026
MarketBeat ·
- Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $30.80
MarketBeat ·
- Evommune Announces Late-Breaker Presentation of Phase 2a Data for
The National Law Review ·
- Q&A: Hereditary Angioedema: Updated Guidelines and Evolving Treatments
Medscape ·
- Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight
Yahoo Finance ·
- EADV26: Key late-stage readouts from the conference
clinicaltrialsarena.com ·
- Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Yahoo Finance ·
- Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Yahoo Finance ·
- Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Yahoo Finance ·
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharmadive.com ·
- Sector Update: Healthcare Stocks Decline in Afternoon Trading
Yahoo Finance ·
- This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
Yahoo Finance ·
Evommune, Inc. key financials
| USD | 2025 | 2024 |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| Net income | -$68.9M | -$66.8M |
| Diluted EPS | $-11.22 | $-45.29 |
| Total assets (year end) | $224.9M | $76.1M |
| Cash and equivalents (year end) | $44.1M | $16.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Evommune, Inc.
- Ticker
- EVMN (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Palo Alto, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 2044725
Frequently asked questions
What exchange is Evommune, Inc. listed on?
Evommune, Inc. trades on the NYSE under the ticker symbol EVMN.
What industry is Evommune, Inc. in?
Evommune, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Evommune, Inc. headquartered?
Evommune, Inc.'s business address on file with the SEC is in Palo Alto, CA.
When does Evommune, Inc.'s fiscal year end?
Evommune, Inc.'s fiscal year ends on December 31.
How much revenue did Evommune, Inc. report?
Evommune, Inc. reported $13.0M in revenue for calendar year 2025, according to its SEC filings.